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Phlegmasia Cerulea Dolens in May
Thurner Syndrome. A threat to life & limb.
Matt McMaster OMS-III, Rage Geringer, MD. Gregory Hicks, MD., Oliwier Dziadkowiec, MD HCA
Introduction
Phlegmasia Cerulea Dolens (PCD) is an uncommon,
severe type of deep venous thrombosis (DVT). The etiology is
usually multifactorial and results in extensive thrombotic
occlusion of major and collateral vasculature. PCD is rare but
more common in patients that have May Thurner Syndrome
(MTS). MTS an anatomical abnormality in which the right iliac
artery compresses the left iliac vein.1 Emergent medical
intervention is required to prevent irreversible limb ischemia and
potentially fatal gangrenous necrosis.2

Case Report
A 76-year-old female who had just completed a 2hour and then subsequent 8-hour flight, was admitted to Sky
Ridge Medical Center for left lower extremity pain, swelling, and
color change. She had a medical history that was significant for
symptoms of one left lower extremity DVT that could not be
confirmed with ultrasound two years before. For the current
admission, the physical examination showed a left lower
extremity with non-pitting edema, 2+ pulses, warmth, and
purplish-blue discoloration. Non-invasive vascular ultrasound of
the left lower extremity showed an extensive, acute-appearing
deformity thrombus involving the left common iliac vein, external
iliac vein, common femoral vein, and deep femoral vein. Acute
4
thrombus as well as May Thurner Syndrome was also seen on
CT-Abdomen Pelvis.
The patient was treated by interventional radiology.
They performed a left common iliac vein recanalization and
reconstruction, a left external iliac vein, common femoral vein,
and superficial femoral vein thrombectomy with on-table
hemolysis (Using heparin and tenecteplase) and left common
iliac vein angioplasty and stenting. The post-procedure
iliofemoral vein ultrasound demonstrated near complete
resolution of the thrombus. The patient was then placed on
1mg/kg of enoxaparin BID for the next 24 hours while being
observed at the hospital, and discharged with a prescription for
prophylactic apixaban.

Discussion

Figures

MTS is anatomic variation in which the left common iliac vein is compressed by
the right common iliac artery. The prevalence of this condition is difficult to estimate because
most patients are asymptomatic. Recent studies suggest that it occurs in 2-5% of patients
undergoing DVT evaluation, and is even more common in women.3
Most DVTs are treated with standard anti-coagulation and thrombectomy as
needed. This approach is not suitable for May Thurner patients with proximal lower extremity
DVTs, however, because it does not address the underlying cause. The compression of the
left common iliac vein in May Thurner patients contributes to stasis which increases their risk
of clot formation, consistent with Virchow’s triad. It is critical that these patients are
recognized so that their acute thrombus can be lysed, and a prophylactic endovascular stent
can also be placed.
MTS causes scar formation such that angioplasty alone for DVT treatment is not
effective. Gao et al studied MTS patients who did not benefit from catheter-directed
thrombolysis with a steady infusion of low-dose urokinase. When these patients were
subsequently treated with low-dose urokinase infusion, endovascular stent placement, and
percutaneous angiography, 81% achieved significant (28% complete and 53% partial)
recanalization. Patency was maintained in 67% of veins 3-24 months later.2 Because the May
Thurner patient in this case did not have a stent placed after her first DVT, it is not surprising
that she developed another DVT on the same leg, and fortunate that her condition was
recognized so a stent could be placed.
Phlegmasia Cerulea Dolens, or “painful blue edema,” is an uncommon
complication of DVTs that is more common in patients with May Thurner Syndrome. It
threatens both life and limb with limb amputation rates of 12-50% and mortality rates of 2040% once diagnosed.3 The most severe complication of Phlegmasia Cerulea Dolens is
venous gangrene that can cause a fatal blood stream infection. This condition is particularly
problematic in patients with other risk factors for DVT including those who are pregnant, have
cancer, smoke, or have stasis promoting anatomic variations such as May Thurner
syndrome.3 For all patients with Phlegmasia Cerulea Dolens, prompt recognition that reverses
the ischemia and prevents future occlusions is critical.
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Fig 1: Four hours after patient
presented to the ED, before
thrombolytic therapy and
endovascular stent placement.

